This web publication constitutes a notice for the purposes of regulation 42ZCZS and regulation 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42CZX, this notice publishes:
- the decisions made by a delegate[1] of the Secretary of the Department of Health, Disability and Ageing (the Delegate) pursuant to regulations 42ZCZR, and 42ZCZW
- the reasons for those final decisions and
- the date of effect of those decisions.
Defined terms:
- In this notice the following defined terms are used in addition to those above:
- the Therapeutic Goods Act 1989 (Cth) (the Act)
- the Scheduling Policy Framework 2018 (the SPF)
- the Scheduling handbook, Guidance for amending the Poisons Standard (the Handbook) and
- the Therapeutic Goods Administration (the TGA).
Note: additional terms are also defined for individual decisions.
Final decisions and reasons
We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.
Contents
- Notice of final decisions to amend (or not amend) the current Poisons Standard
- Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #40, March 2025)
- Methyl ethyl ketone oxime (MEKO)
- Acrylates and methacrylates based on bisphenol A (BPA)
- Medium and long chain alkyl sulfates
- Sodium hydroxide and potassium hydroxide
- Cyanoacrylate esters
- Final decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACMS-ACCS #39, March 2025)
- Chromium-DL methionine
- Final decisions on proposed amendments to the current Poisons Standard under regulation 42ZCZW
- Bromoxynil
- Mitragyna speciosa (kratom)
- Decision to amend the current Poisons Standard under section 52D(2) of the Act
- WIN 55,212-2
- Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
- Anacaulase-bcdb
- Apadamtase alfa
- Avacincaptad pegol
- Capmatinib
- Depemokimab
- Deutivacaftor
- Orebrutinib
- Pirtobrutinib
- Plozasiran
- Remibrutinib
- Retifanlimab
- Vanzacaftor
[1] For the purposes of s 52D of the Therapeutic Goods Act 1989 (Cth).